Ten pharmaceutical manufacturers are signing the Inflation Reduction Act's Medicare drug price negotiation program. These companies are Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Boehringer Ingelheim, Immunex, Janssen Pharmaceuticals, Pharmacyclics, Merck & Company (MRK), Janssen Biotech, Novartis (NVS), and Novo Nordisk (NVO), according to the Biden Administration. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction1 Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system2–4 IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide5–9 Novar
Novartis (NVS) closed the most recent trading day at $101.86, moving -0.46% from the previous trading session.